{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.31","upperLimit":"5.16","value":"2.79"},{"groupId":"OG001","lowerLimit":"2.76","upperLimit":"2.79","value":"2.78"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Progression Free Survival is defined as the interval between the date of T-cell infusion and the initial assessment date of confirmed progressive disease as assessed by the investigator per IMWG (2016) or date of death. Progressive disease is defined as an increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \\>=0.5 grams per deciliter (g/dL); Serum M-protein increase \\>=1 g/dL if the lowest M-component was \\>=5 g/dL; Urinary M-protein (absolute increase must be \\>=200 mg per 24 hours).","dispersionType":"Inter-Quartile Range","groups":[{"description":"Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single intravenous (IV) infusion of GSK3377794.","id":"OG000","title":"GSK3377794"},{"description":"Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108.","id":"OG001","title":"GSK3377794+Pembrolizumab"}],"paramType":"MEDIAN","populationDescription":"Modified ITT Population","reportingStatus":"POSTED","timeFrame":"Up to 108 weeks","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"Months"}